Our Take
One failed trial does not indict a drug class, but a pattern of failures across multiple sponsors and indications suggests the LAG-3 target may be harder to exploit than immunology initially believed.
Why it matters
LAG-3 was positioned as a logical complement to PD-1 and PD-L1 checkpoint inhibitors, but repeated clinical setbacks signal that the mechanism may lack sufficient therapeutic window or that patient selection remains unsolved. Sponsors betting on LAG-3 as a near-term revenue driver need to reassess portfolio priority.
Do this week
Immunology investors: audit your LAG-3 exposure across your portfolio companies and request updated clinical timelines and mechanism-of-action data from management before Q4 planning cycles close.
Fianlimab stumbles in melanoma
Regeneron Pharmaceuticals announced that fianlimab, its LAG-3 inhibitor, failed to meet its primary endpoint in a Phase 3 trial for skin cancer. The company did not disclose efficacy figures or comparators in the available statement, but the miss marks the latest clinical setback for the LAG-3 drug class. Multiple other sponsors have reported disappointing results with LAG-3-targeted candidates in recent months, according to the source.
LAG-3 credibility eroding across the sector
LAG-3 inhibitors entered late-stage development on the back of strong preclinical and early clinical data suggesting they could work synergistically with established checkpoint inhibitors like PD-1 and PD-L1 blockers. The rationale was sound: blockade of a second immune checkpoint should broaden T-cell activation and overcome resistance. But the clinic has not cooperated. Repeated Phase 3 failures across different LAG-3 programs and tumor types suggest either that the target itself is harder to hit than expected, that the patient populations being tested were not selected properly for LAG-3 response, or that the therapeutic window is narrower than preclinical models implied.
For Regeneron, the miss adds pressure to a portfolio that was counting on fianlimab to extend its immunology franchise beyond its established PD-L1 asset. For the sector, it raises a harder question: whether LAG-3 will be salvageable through better biomarkers, patient stratification, or combination strategies, or whether it is simply a less tractable target than the first wave of checkpoint inhibitors.
Reassess LAG-3 in your pipeline
If you hold LAG-3 exposure via investments in clinical-stage or discovery programs, request detailed readouts from management on why their candidate may perform differently from recent failures. Ask for biomarker strategies and patient selection criteria. Do not assume the failure is generic to the class without evidence that your program addresses the specific liability (pharmacology, dosing, patient population, or combination strategy) that sank competitors. For those without skin in the game, watch whether LAG-3 becomes a contrarian bet (teams willing to take asymmetric risk on better science) or a cautionary tale (capital fleeing toward safer checkpoint mechanisms).